We are live on ! Find out more
GYRE icon

Gyre Therapeutics

43 hedge funds and large institutions have $6.39M invested in Gyre Therapeutics in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

16% less funds holding

Funds holding: 51 → 43 (-8)

17.08% less ownership

Funds ownership: 47.91% → 30.83% (-17%)

53% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 17

80% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 10

94% less capital inflows, than outflows

Capital inflows: $250K | Capital outflows: $4.49M

Holders
43
Holders Change
-8
Holders Change %
-15.69%
% of All Funds
0.68%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
8
Reduced
17
Closed
10
Calls
$165​K
Puts
–
Net Calls
+$165​K
Net Calls Change
-⁠$270​K

GYRE Hedge Fund Activity: Q1 2022 in Review

43 of the 6,366 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2022, worth a combined $6.39M — down 54% from $13.7M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of GYRE and 2 opened new positions — a net loss of 8 holders — while 17 trimmed existing stakes and 8 added.

The largest buyer was Sabby Management, adding an estimated $120K. The largest seller was OrbiMed, exiting entirely with an estimated $1.58M sold.

  • 43 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2022, down from 51 in Q4 2021.
  • Funds reported $6.39M of Gyre Therapeutics stock for Q1 2022, down 54% quarter-over-quarter.
  • 2 funds opened new Gyre Therapeutics positions in Q1 2022 and 10 closed out, a net change of -8 holders.
  • The largest Gyre Therapeutics buyer in Q1 2022 was Sabby Management, an estimated $120K added.
  • The largest Gyre Therapeutics seller in Q1 2022 was OrbiMed, an estimated $1.58M sold.

Based on aggregated 13F filings for Q1 2022.